|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction显示文摘AIM: To determine the optimal method of endoscopic preoperative biliary drainage for malignant distal biliary obstruction.METHODS: Multicenter retrospective study was conducted in patients who underwent plastic stent(PS) or nasobiliary catheter(NBC) placement for resectable malignant distal biliary obstruction followed by surgery between January 2010 and March 2012. Procedurerelated adverse events, stent/catheter dysfunction(occlusion or migration of PS/NBC, developmentof cholangitis, or other conditions that required repeat endoscopic biliary intervention), and jaundice resolution(bilirubin level < 3.0 mg/d L) were evaluated. Cumulative incidence of jaundice resolution and dysfunction of PS/NBC were estimated using competing risk analysis. Patient characteristics and preoperative biliary drainage were also evaluated for association with the time to jaundice resolution and PS/NBC dysfunction using competing risk regression analysis.RESULTS: In total, 419 patients were included in the study(PS, 253 and NBC, 166). Primary cancers included pancreatic cancer in 194 patients(46%), bile duct cancer in 172(41%), gallbladder cancer in three(1%), and ampullary cancer in 50(12%). The median serum total bilirubin was 7.8 mg/d L and 324 patients(77%) had ≥ 3.0 mg/d L. During the median time to surgery of 29 d [interquartile range(IQR), 30-39 d]. PS/NBC dysfunction rate was 35% for PS and 18% for NBC [Subdistribution hazard ratio(SHR) = 4.76; 95%CI: 2.44-10.0, P < 0.001]; the pig-tailed tip was a risk factor for PS dysfunction. Jaundice resolution was achieved in 85% of patients and did not depend on the drainage method(PS or NBC).CONCLUSION: PS has insufficient patency for preoperative biliary drainage. Given the drawbacks of external drainage via NBC, an alternative method of internal drainage should be explored. | Naoki Sasahira Tsuyoshi Hamada Osamu Togawa Ryuichi Yamamoto Tomohisa Iwai Kiichi Tamada Yoshiaki Kawaguchi Kenji Shimura Takero Koike Yu Yoshida Kazuya Sugimori Shomei Ryozawa Toshiharu Kakimoto Ko Nishikawa Katsuya Kitamura Tsunao Imamura Masafumi Mizuide Nobuo Toda Iruru Maetani Yuji Sakai Takao Itoi Masatsugu Nagahama Yousuke Nakai Hiroyuki Isayama | 2016 | World Journal of Gastroenterology2016，22，14： | 18 |
| 2 | Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication显示文摘 | Paul Lochhead Aya Kuchiba Yu Imamura Xiaoyun Liao Mai Yamauchi Reiko Nishihara Zhi Rong Qian Teppei Morikawa Jeanne Shen Jeffrey A. Meyerhardt Charles S. Fuchs Shuji Ogino | 2013 | JNCI Journal of the National Cancer Institute2013，，15： | 3 |
| 3 | CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc ? and Thereby Promotes Tumor Growth显示文摘 | Takatsugu Ishimoto Osamu Nagano Toshifumi Yae Mayumi Tamada Takeshi Motohara Hiroko Oshima Masanobu Oshima Tatsuya Ikeda Rika Asaba Hideki Yagi Takashi Masuko Takatsune Shimizu Tomoki Ishikawa Kazuharu Kai Eri Takahashi Yu Imamura Yoshifumi Baba Mitsuyo O | 2011 | Cancer Cell2011，，3： | 2 |
| 4 | High glucose level and free fatty acid stimulates reactive oxygen speies production through protein knase C-dependent activation of NADP(H)oxidase in culture vascular cells显示文摘 | Inoguchi T Li P Umeda F Yu HY Kakimoto M Imamura M | 2000 | Diabetes2000，49，11： | 1 |
| 5 | Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase c activity in cultured aortic smooth muscle cells显示文摘 | H. Y. Yu T. Inoguchi M. Kakimoto N. Nakashima M. Imamura T. Hashimoto F. Umeda H. Nawata | 2001 | Diabetologia2001，，5： | 1 |
| 6 | Identification of the NiemannPick C1-like 1cholesterol a bsorption receptor as a new hepatitis C virus entry factor显示文摘 | Sainz B Jr Barretto N Martin D N Hiraga N Imamura M Hussain S Marsh K A Yu X Chayama K Alrefai W A Uprichard S L | 2012 | Nat Med2012，18，2： | 1 |
| 7 | 显示文摘 | Inoguchi T Yu HY Imamura M | 2001 | Med Electron Microsc2001，34，2： | 1 |
| 8 | p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma显示文摘 | Asuka Murata Yoshifumi Baba Masayuki Watanabe Hironobu Shigaki Keisuke Miyake Ryuichi Karashima Yu Imamura Satoshi Ida Takatsugu Ishimoto Shiro Iwagami Yasuo Sakamoto Yuji Miyamoto Naoya Yoshida Hideo Baba | 2013 | Medical Oncology2013，，4： | 1 |
| 9 | Usefulness of Transcription–Reverse Transcription Concerted Reaction Method for Detecting Circulating Tumor Cells in Patients With Colorectal Cancer显示文摘 | Nobutaka Sato Naoko Hayashi Yu Imamura Yohei Tanaka Koichi Kinoshita Jyunji Kurashige Seiya Saito Ryuichi Karashima Kotaro Hirashima Yohei Nagai Yuji Miyamoto Masaaki Iwatsuki Yoshifumi Baba Masayuki Watanabe Hideo Baba | 2012 | Annals of Surgical Oncology2012，，6： | 1 |
| 10 | Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma显示文摘 | Kotaro Hirashima MD Yoshifumi Baba MD PhD Masayuki Watanabe MD PhD Ryu-ichi Karashima MD Nobutaka Sato MD Yu Imamura MD PhD Yukiharu Hiyoshi MD PhD Yohei Nagai MD Naoko Hayashi MD PhD Ken-ichi Iyama MD PhD Hideo Baba MD PhD | 2010 | Annals of Surgical Oncology2010，，9： | 1 |
| 11 | Altered gap junction activity in cardiovascular tissues of diabetes 显示文摘 | Inoguchi T Yu HY Imamura M | 2001 | Med Electron Microse2001，34，2： | 1 |
| 12 | Adenoviral Oncolytic Suicide Gene Therapy for a Peritoneal Dissemination Model of Gastric Cancer in Mice显示文摘 | Yu Imamura Shinji Ishikawa Nobutaka Sato Ryuichi Karashima Kotaro Hirashima Yukiharu Hiyoshi Youhei Nagai Yoshikatsu Koga Naoko Hayashi Masayuki Watanabe Gen Yamada Hideo Baba | 2010 | Annals of Surgical Oncology2010，，2： | 1 |
| 13 | Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors显示文摘 | Zhi Rong Qian Monica Ter-Minassian Jennifer A. Chan Yu Imamura Susanne M. Hooshmand Aya Kuchiba Teppei Morikawa Lauren K. Brais Anastassia Daskalova Rachel Heafield Xihong Lin David C. Christiani Charles S. Fuchs Shuji Ogino Matthew H. Kulke | 2013 | Journal of Clinical Oncology2013，，27： | 1 |
| 14 | Increased Resistance of Contact Lens-Related Bacterial Biofilms to Antimicrobial Activity of Soft Contact Lens Care Solutions显示文摘 | Loretta B Szczotka-Flynn Yoshifumi Imamura Jyotsna Chandra Changping Yu Pranab K Mukherjee Eric Pearlman Mahmoud A Ghannoum | 2009 | Cornea2009，，8： | 1 |
| 15 | p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma显示文摘 | Asuka Murata Yoshifumi Baba Masayuki Watanabe Hironobu Shigaki Keisuke Miyake Ryuichi Karashima Yu Imamura Satoshi Ida Takatsugu Ishimoto Shiro Iwagami Yasuo Sakamoto Yuji Miyamoto Naoya Yoshida Hideo Baba | 2013 | Medical Oncology2013，，4： | 1 |
| 16 | Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers显示文摘 | Yu Imamura Teppei Morikawa Xiaoyun Liao Paul Lochhead Aya Kuchiba Mai Yamauchi Zhi Rong Qian Reiko Nishihara Jeffrey A. Meyerhardt Kevin M. Haigis Charles S. Fuchs Shuji Ogino | 2012 | Clinical Cancer Research2012，，17： | 1 |
| 17 | High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C dependent activation of NAD(P)H oxidase in cultured vascular cells显示文摘 | Inoguchi T Li P Umeda F Yu H Y Kakimoto M Imamura M | 2000 | Diabetes2000，49，： | 1 |
| 18 | Effects of the compatibility of a polyacrylic block copolymer/tackifier blend on the phase structure and tack of a pressure-sensitive adhesive显示文摘 | Yoshinobu Nakamura Yu Sakai Keigo Imamura | 2012 | Journal of AppliedPolymer Science2012，123，5： | 1 |
| 19 | Recent updates of therapeutic strategy of esophagogastric junction adenocarcinoma显示文摘The incidence of esophagogastric junction(EGJ)adenocarcinoma has been increasing in Asian countries.Despite the recent advances in multidisciplinary treatments,EGJ adenocarcinoma remains aggressive with unfavorable outcomes.Regarding surgical strategy,EGJ adenocarcinoma arises between the esophagus and the stomach,and thus tumor cells spread through the lymphatic system both upward to the mediastinum and downward to the abdomen.Nevertheless,an optimal extent of lymphadenectomy remains controversial.Regarding drug therapy,the latest topic in gastric and EGJ adenocarcinoma is trastuzumab deruxtecan,which is an antibody-drug conjugate consisting of an anti-HER2 antibody.In addition,many clinical trials have recently demonstrated the efficacy of immune checkpoint inhibitors.Meanwhile,recent advances in sequencing technology have revealed that gastroesophageal adenocarcinoma could be categorized into four molecular subtypes:epstein-Barr virus-associated,high-level microsatellite instability,genomically stable,and chromosomal instability tumors.Furthermore,these subtypes show distinct clinical phenotypes and molecular alterations.We review the current surgical strategy and drug treatment such as molecular-targeted agents,immune checkpoint inhibitors,and molecular-subtype-based therapeutic strategies in EGJ adenocarcinoma.Clinical and molecular characteristics and response to immune checkpoint inhibitors differ among molecular subtypes.Treatment strategies based on molecular subtypes may be clinically beneficial for patients with EGJ adenocarcinoma. | Suguru Maruyama Yu Imamura Yasukazu Kanie Kei Sakamoto Daisuke Fujiwara Akihiko Okamura JunKanamori Masayuki Watanabe | 2021 | Journal of Cancer Metastasis and Treatment2021，7，1： | 0 |
| 20 | Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors显示文摘Background:Antiangiogenic tyrosine kinase inhibitors(TKIs)provide one of the few therapeutic options for effective treatment of hepatocellular carcinoma(HCC).However,patients with HCC often develop resistance toward antiangiogenic TKIs,and the underlying mechanisms are not understood.The aim of this study was to determine the mechanisms underlying antiangiogenic TKI resistance in HCC.Methods:We used an unbiased proteomic approach to define proteins that were responsible for the resistance to antiangiogenic TKIs in HCC patients.We evaluated the prognosis,therapeutic response,and serum insulin-like growth factor-binding protein-1(IGFBP-1)levels of 31 lenvatinib-treated HCC patients.Based on the array of results,a retrospective clinical study and preclinical experiments using mouse and human hepatoma cells were conducted.Additionally,in vivo genetic and pharmacological gain-and loss-of-function experiments were performed.Results:In the patient cohort,IGFBP-1 was identified as the signaling molecule with the highest expression that was inversely associated with overall survival.Mechanistically,antiangiogenic TKI treatment markedly elevated tumor IGFBP-1 levels via the hypoxia-hypoxia inducible factor signaling.IGFBP-1 stimulated angiogenesis through activation of the integrinα5β1-focal adhesion kinase pathway.Consequently,loss of IGFBP-1 and integrinα5β1 by genetic and pharmacological approaches re-sensitized HCC to lenvatinib treatment.Conclusions:Together,our data shed light onmechanisms underlying acquired resistance of HCC to antiangiogenic TKIs.Antiangiogenic TKIs induced an increase of tumor IGFBP-1,which promoted angiogenesis through activating the IGFBP-1-integrinα5β1 pathway.These data bolster the application of a new therapeutic concept by combining antiangiogenic TKIs with IGFBP-1 inhibitors. | Hiroyuki Suzuki Hideki Iwamoto Takahiro Seki Toru Nakamura Atsutaka Masuda Takahiko Sakaue Toshimitsu Tanaka Yasuko Imamura Takashi Niizeki Masahito Nakano Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Miwa Sakai Kazutoyo Morita Masamichi Nakayama Tomoharu Yoshizumi Ryoko Kuromatsu Hirohisa Yano Yihai Cao Hironori Koga Takuji Torimura | 2023 | Cancer Communications2023，43，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员